#rarediseases #MHRA #UK #PIMdesignation #UCB #DoxTM #TK2d #ThymidineKinase2Deficiency #TK2Deficiency #patientaccess #TK2geneticmutation #mitochondrialDNAdepletion #EarlyAccesstoMedicines #EAMS #MitochondrialMedicine #Mitochondrialdiseases
pharmatimes.com/news/mhra-gr...
pharmatimes.com/news/mhra-gr...
MHRA grants Promising Innovative Medicine designation to UCB’s DoxTM for TK2d - PharmaTimes
UCB’s developmental treatment may be eligible for patient access
pharmatimes.com
May 12, 2025 at 9:46 AM